Finanzen von Seres Therapeutics Inc (MCRB)MCRBSeres Therapeutics Inc

Evaluating the bottom line, Seres Therapeutics, Inc. maintains a gross margin of 18.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2723.78%, while the net margin is -2746.37%. These profitability ratios, combined with a Return on Equity (ROE) of -144.35%, provide a clear picture of how effectively MCRB converts its operational activities into shareholder value.

In the context of the broader market, MCRB competes directly with industry leaders such as JSPR and MRKR. With a market capitalization of $20.09M, it holds a leading position in the sector. When comparing efficiency, MCRB's gross margin of 18.89% stands against JSPR's N/A and MRKR's N/A. Such benchmarking helps identify whether Seres Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a significant improvement in its financial performance, with a gross margin of 100% in Q3 2025 and a net income of $4.6 million in Q2 2026, indicating effective cost management and operational efficiency. However, the overall revenue remains modest, with total revenue of $0.78 million reported for FY 2026.